february 2014: Support from SAKK
FEBRUARY 2014: SUPPORT FROM SAKK
INNOMEDICA RECEIVES SUPPORT FROM THE SAKK
InnoMedica and the Swiss Group for Clinical Cancer Research ( SAKK ) hope to gain from the development of new cancer drug TLD -1 improved efficacy and fewer side effects for patients with cancer.
In the planning and conduct of clinical trials InnoMedica is supported by the SAKK that performs as an independent organization multicenter clinical trials along with the cancer centers in Swiss hospitals . After completion of the preclinical phase in winter 2014, the first application in patients is to be performed in the fall of 2015. In clinical trials Phase I and II, the efficacy and tolerability of the drug in the patient is examined.
The SAKK is a nonprofit organization that is committed as a cooperative group of the multi-center clinical cancer research since 1965. Based on a performance agreement with the Federal Government the SAKK as an academic, decentralized research institute carries out clinical trials in all major hospitals in Switzerland and operates on an international level together with cooperative groups abroad. The aim is to develop existing cancer treatments for patients and to investigate the efficacy and tolerability of new therapies. www.sakk.ch
More on Press Releases.